Summary A monoclonal antibody (L.1), reacting in vitro specifically with L1210 leukaemia cells in a complement-dependent cyctotoxicity assay (CDC), has been exploited for serotherapy studies. Different regimens of L.1 treatment of CD2F1 mice bearing the semi-syngeneic L1210 leukaemia did not prolong the life span of tumor-bearing animals. Moreover, the administration of L.1 did not enhance the antitumour effects of cyclophosphamide. Studies of in vivo localization showed that L.1 was able to bind specifically to L1210 leukaemic cells, although 30-40% of the cells remained negative. The presence of L.1 in mouse blood was demonstrated up to 15 days after the inoculation. On the other hand, in vivo administration of L.1 was probably accompanied by loss of the cytotoxic activity, perhaps through a mechanism of complement inactivation, since the presence of undiluted normal mouse serum in a CDC assay inhibited the cytotoxic activity of L.1. Moreover, serum from L.1-treated mice did not display any cytotoxic activity, although the presence of the antibody could be demonstrated by indirect immunofluorescence.
The treatment of malignant diseases by passive administration of antibodies (Wright & Bernstein 1980) has been pursued as a promising therapy, although the life span after antiserum administration has not so far been improved. The failure of conventional serotherapy has been mainly attributed to the low specificity of the antisera and the poor immunogenicity of tumour-associated antigens (TAA). The new era in serology since hybridoma technology (Kohler & Milstein 1975) was devised might be exploited for new modalities of cancer immunotherapy.
Tumour-specific antigens and specific antibodies are the basic necessities for successful passive immunotherapy of cancer. Although tumourspecific antigens in human tumours (Metzgar et al., 1981; Iwaki et al., 1982; Ball et al., 1982) have not yet been definitely demonstrated, monoclonal antibodies (MAb) highly specific to TAA (Gunn et al., 1981) or to tissue and differentiation antigens (Kirch & Hammerling, 1981) might provide optimal tools to study the anti-tumour efficacy of passive serotherapy (Kirch & Hammerling, 1981; Bernstein et al., 1980; Scheinberg & Strand 1982; Ritz et al., 1981; Trowbridge & Lopez, 1982; Sears et al., 1982) .
In a previous report from this laboratory (Testorelli et al., 1982) , the production and the characterization of a MAb reacting specifically with the cells of the L1210 murine leukaemia (L.1) was described. The L.1 MAb displayed in vitro very high and specific complement-dependent cytotoxicity against L1210 cells. On the other hand, it did not react with normal adult and foetal murine tissues, with cells from several independent haplotypes or with a number of chemical-and virus-induced experimental tumours.
In the present report, the therapeutic effects of the administration of L.1 alone or combined with chemotherapeutic agents on the survival rates of leukaemic mice are presented. Possible reasons for the ineffectiveness of serotherapy with L.1 were also investigated and are discussed.
Materials and methods
Correspondence: C. Testorelli; Institute of Pharmacology, School of Medicine, Via Vantivelli 32, 20129 Milano, Italy. Received 8 August 1982 , accepted 25 November 1982 Animals and tumours Inbred DBA/2, Balb/c and hybrid (Balb/c x DBA/2) CD2F1 male mice, 10-15 weeks old, were obtained from Charles River (Calco, Italy). L1210/Cr leukaemia was maintained by weekly passages (i.p.) into compatible CD2F1 mice. Balb/c or CD2F1 mice were used to produce antibody-containing ascites.
Hybrid cell lines and production of ascitic fluid The production of the hybridoma cell line secreting the monoclonal antibody L. 1 (IgM) to a surface antigen of L1210 cells has been described previously (Testorelli et al., 1982) . The Complement-dependent cytotoxicity assay (CDC) 51Cr-release assay was performed as described elsewhere (Testorelli et al., 1982 (Ozato et al., 1980 Results of time-course experiments are also illustrated in Figure 1 . The % of L. 1 + ve cells analysed by automatic flow fluorocytometry peaked Table IV incubation-with rabbit complement. However, full susceptibility to complement-mediated lysis was obtained upon cell re-exposure to L. I in vitro.
Studies of L. I properties after in vivo administration
The time course of blood L.1 levels in CD2F1 mice, as evaluated by IMF (dashed line) or by the 51Cr-release assay (full line), was studied ( Figure 3 ). look (Table V) . However, a normal lytic reaction was observed when the mouse serum was removed before the addition of complement.
L1210 antigen in mousefluids
The detectability of antigen recognized by L.1 shed by tumour cells into the blood or the ascites of L1210-bearing mice was examined. Inhibition of cytotoxic activity of L.1 by serum and ascites fluid from leukaemic mice obtained at varying intervals after the challenge is reported in Figure 4 . The inhibitory capacity of mouse fluids, not detectable until 4 days after the tumour inoculation, increased rapidly thereafter and was more impressive for the ascites fluid than for the serum. Titration of soluble antigen ( Figure 5) showed that a relatively large amount of free antigen was detectable in the ascites fluid on day 7, whereas a lesser degree of inhibitory activity was demonstrable on day 5. 
Discussion
In principle, specific and cytotoxic MAb should provide selective bullets for the in vivo eradication of cancerous cells leaving normal cells undamaged. These theoretical conditions, hypothesized since the Ehrlich era, were obtained in our laboratory by the production of L.1. In fact, L.1 is absolutely specific to L1210 leukaemic cells and as an IgM immunoglobulin displays great efficiency in fixing complement (Testorelli et al., 1982 Although blood clearance of L.1 in the mouse had the half life already described by others for the same antibody class Kirch & Hammerling 1981) , blood serum samples containing L.1 and complement did not lyse L1210 cells in vitro. Furthermore, complement from different sources mixed with mouse serum in vitro was completely inactivated.
Antigen shedding cannot be responsible for the failure of L. 1 serotherapy since, at the start of serotherapy, soluble antigen was not found in body fluids. L. 1 inhibition by mouse serum and even more by ascites fluid from tumour-bearing mice became evident 4 days after L1210 challenge. Therefore, circulating antigen might negatively influence late treatments only.
The experimental system used in these studies although adhering to optimal theoretical conditions, did not bring about increased survival time for leukaemic mice. Incomplete antibody binding to target cells and blood inactivation of complement might be major factors in these disappointing results.
A number of claims (Kirch & Hammerling, 1981; Bernstein et al., 1980; Scheinberg & Strand 1982; Miller & Levy, 1981; Ritz et al., 1980; Trowbridge & Lopez 1982; Herlyn & Koprowski, 1981) , of therapeutic benefit from the use of MAb in cancer therapy have been reported recently in the literature. Partial successes in tumour systems other than that used here could be attributed to different Ig isotypes, acting through an antibody-dependent cellular cytotoxicity (ADCC) rather than complement-mediated lysis. The limited achievements of this approach might result in greater efforts (Pimm et al., 1982; Raso et al., 1982) to exploit monoclonal technology to carry toxic compounds specifically to their target cells.
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